Search Results for: geron

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy

Cell-Cure-Logo

Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based …

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy Read More »

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial

jane-lebkowski

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung …

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »

Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product

ViaCyte-logo-3x2

Type 1 Diabetes is a huge global problem. Where are the solutions that would compliment or replace insulin therapy for diabetics? There haven’t been too many that have gotten very far, which makes the news of a potential stem cell-based therapy moving along in the pipeline all the more exciting. ViaCyte (see more posts here, …

Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product Read More »

TGIF stem cell headlines of week: Asterias, lasers, immunity, & more

Laser-tooth-stem-cells

It’s been an important week for stem cells. Although I’ve been busy working on multiple grants and papers, when I take a break I like to read up on what’s been going on with stem cells. What are the top stem cell stories and headlines of the week? CIRM awarded Asterias (a subsidiary of BioTime) …

TGIF stem cell headlines of week: Asterias, lasers, immunity, & more Read More »

Has anti-aging finally come of age with Google’s Calico?

Can Google’s new anti-aging company, Calico, have you Googling at age 140? Don’t sell your burial plot just yet. The idea of anti-aging has been around for a very long time and efforts to combat aging have spanned millennia largely without any success so Calico (apparently short for California Life Company, which sounds more like …

Has anti-aging finally come of age with Google’s Calico? Read More »

Dozen Candidates To Be New CIRM President

CIRM-

Who might make a fantastic new CIRM President? The California stem cell community is abuzz with this question. This new President will not only lead CIRM today, but also in all likelihood will steer CIRM in its new incarnation after 2017, what I’ve called CIRM 2.0. At least that would be ideal. CIRM has posted a …

Dozen Candidates To Be New CIRM President Read More »

Mike West Interview Part 3: key flaw in stem cell field

Michael-West-PhD-CEO-of-BioTime-1-934x10241

I’m doing a series of posts on my recent conversation with BioTime CEO and pioneer of the stem cell field, Dr. Mike West. You can read Part 1 and Part 2 on Geron, ACT, and the history of the pluripotent stem cell field, particularly embryonic stem cells (ESCs). Today in Part 3, I am focusing on …

Mike West Interview Part 3: key flaw in stem cell field Read More »

Interview with BioTime CEO Michael West Part 1: a little stem cell history

Michael-West-PhD-CEO-of-BioTime-1-934x10241

It was my pleasure recently to  talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock …

Interview with BioTime CEO Michael West Part 1: a little stem cell history Read More »